Kitov Pharmaceuticals Holdings Ltd. (KTOV)
(Delayed Data from NSDQ)
$1.07 USD
+0.04 (3.88%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.06 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Purple Biotech Ltd. Sponsored ADR [KTOV]
Reports for Purchase
Showing records 1 - 20 ( 22 total )
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
CM24 Trial Expansion Into Pancreatic Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
Clinical Trials Advancing; ADS Ratio Change; Reiterate Buy; Raising PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
Lengthy Cash Runway; Multiple Catalysts; Lowering PT to $3 Due to Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
Multiple Recent Value-Driving Catalysts; Consensi Launch Imminent; Reiterate Buy and Modulating Target to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
Positive Preclinical NT219 Data Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
Consensi- Wins FDA Approval; Cash Replenished; Reiterate Buy and Raising Target to $12.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
China Partnership the Perfect Runway Into Approval Decision; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
Consensi PDUFA Date Around the Corner; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
Recent Developments Outweigh ISA Investigation Risk; Upgrading to Buy With $10 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
Investigation Started by Israeli Securities Authority; Placing Rating and Price Target Under Review
Provider: Rodman & Renshaw, Co.
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
Investigation Started by Israeli Securities Authority; Placing Rating and Price Target Under Review
Provider: H.C. Wainwright & Co., Inc.
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
U.S. Patent Claims Granted; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
U.S. Patent Claims Granted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
New Clinical Data Released; Financing Completed; Reducing Price Target
Provider: Rodman & Renshaw, Co.
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
New Clinical Data Released; Financing Completed; Reducing Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
Recent Updates Reflect Positive Progress; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
Recent Updates Reflect Positive Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
Steadily Approaching NDA Filing; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Unclassified
Steadily Approaching NDA Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.